LAUSR

of to of these tumors is challenging and involves not only surgical resection but also some adjuvant treatment. for the meningioma grade III treatment, pharmacotherapy be considered; however, it is still evidence level IV. 1 Bevacizumab is an anti-angiogenic therapy, a monoclonal antibody that binds to the VEGF-A isoforms and thereby inhibits the activation of VEGF signaling pathways, avoiding neovascularization. 2 It is a promising medication for non-benign meningiomas. Bai published an interesting article regarding the treatment of this condition. It is a retrospective study with a robust sample considering the rareness of these conditions. They could observe a homogeneous sample between both groups, and the results revealed better outcomes considering progression-free survival (PFS) and overall survival (OS) for the patients who were treated with the bevacizumab protocol. 3 These findings are inspiring and promising. However, some considerations should be made. Usually, it is recom-mended to perform stereotactic radiosurgery or fractionated radiotherapy after resection of meningiomas grades II and III, even in gross total resection. 1 This was not cited by the author. This could lead to different outcomes considering unbalanced groups for this adjuvant treatment. Gamma knife was performed just after the recurrence. of the